GRAIL Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • GRAIL's estimated annual revenue is currently $382.2M per year.(i)
  • GRAIL received $300.0M in venture funding in May 2018.
  • GRAIL's estimated revenue per employee is $248,000
  • GRAIL's total funding is $2B.
  • GRAIL's current valuation is $2.5B.

Employee Data

  • GRAIL has 1541 Employees.(i)
  • GRAIL grew their employee count by 20% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

GRAIL is a life sciences company whose mission is to detect cancer early, when it can be cured. GRAIL is using the power of high-intensity sequencing, population-scale clinical trials, and state of the art Computer Science and Data Science to enhance the scientific understanding of cancer biology and develop blood tests for early-stage cancer detection. The company has secured over $1B in venture funding led by ARCH Venture Partners and including Amazon, Bezos Expeditions, Bill Gates, Bristol-Myers Squibb, Celgene, GV, Illumina, Johnson & Johnson Innovation, Merck, McKesson Ventures, Sutter Hill Ventures, Tencent, Varian Medical Systems, and other financial partners. If you're ready to join a mission with meaning, bring your passion to GRAIL. Together we will make history in the fight against cancer.

keywords:Biotechnology, Life Sciences, Healthcare, Diagnostics, Medical Technologies, Medical Device


Total Funding


Number of Employees


Revenue (est)


Employee Growth %






2022-04-20 - The Holy Grail Of Dodge Chargers Is For Sale

Ask anyone who's into muscle cars which car of the 1960s and 70s best represents that era, and the Dodge Ch...

2022-04-17 - ‘Monty Python and the Holy Grail’ returns to the big screen at the Newtown Theatre

NEWTOWN BOROUGH Run away! Run away! To the historic Newtown Theatre on Friday, May 20 when the theatre brings “Monty Python and the Holy...

2022-04-17 - We Put New Cancer Screens to the Test. What We Learned.

A raft of multicancer blood tests are under development that promise early detection. Our verdict on Grail's Galleri: An exciting innovation...

2021-07-25 - Would Illumina’s acquisition of GRAIL constrict the expansion of the liquid biopsy space?

Earlier this year, the Federal Trade Commission’s (FTC) posed a roadblock in the path of sequencing giant Illumina’s $7.1 billion proposed acquisition of Grail, a healthcare company focusing on early cancer detection, and importantly, a 2016 spin-out from the former. Right now, the European Comm ...

2020-09-21 - Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal

Biotech has become one of the hottest areas of venture investment in recent years, as progress in machine learning, genetics, medical devices and biology fuse together into new products for the gargantuan health industry. Case in point: Grail, which began in 2016 as a spinoff from genetic seque ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

GRAIL Funding

DateAmountRoundLead InvestorsReference
2017-03-02$900.0MBArch Venture PartnersArticle
2017-11-23$1211.7MBARCH Venture PartnersArticle
2018-05-22$300.0MCAlly Bridge GroupArticle

GRAIL Executives

Joshua OfmanPresident and Chief Medical Officer
Raakhee KumarAssociate General Counsel & Chief Compliance Officer
Aaron FreidinChief Financial Officer
Satnam AlagSenior Vice President Software Engineering and Chief Security Officer
Tracy DachenhausenDirector, Clinical Development Strategy | Chief of Staff (COS)
Bob RagusaChief Executive Officer
Harpal KumarPresident of GRAIL Europe
Joshua OfmanPresident and Chief Medical Officer
Paul CiccolellaSenior Vice President, Global Technology & Operations
Matt BurnsVP, Head of Communications
Abram BarthVP, Head of Legal; Privacy Officer
Byoungsok JungVP of R&D
Rita ShaknovichVP, Medical Affairs
Satnam AlagSenior Vice President Software Engineering and Chief Security Officer
Deepshikha BhandariVice President Regulatory Affairs
Megan HallVice President, Medical Affairs
Harpal KumarPresident
Mitch LewandowskiVice President, Quality
Eric FungVice President Clinical Development
Andrew CrenshawVice President Operations, Site Lead
Michael VicariVice President Sales, Grail
Christina DurEpidemiology Vice President, Distinguished Scientist
Joan MalcolmVice President, Strategic Partnerships and Initiatives
Joe McKennaVice President of Commercial Partnerships & Growth Strategy
Sir KumarPresident
Trish RowlandVice President Corporate Communications
Wendy StraitVice President of Customer Success